NSE:NOVARTIND (India)
Â
Shs Dematerialised
₹
1,486.3
-15.9 (-1.06%)
Aug 25
Business Description
Novartis India Ltd
ISIN : INE234A01025
Share Class Description:
NSE:NOVARTIND: Shs DematerialisedTotal Employee Number:
61Compare
Compare
Traded in other countries / regions
500672.India IPO Date
1998-08-19Description
Novartis India Ltd is an Indian-based pharmaceutical company. The company is engaged in the trading of Drugs and Pharmaceuticals. It derives revenue from operations in India. The company operates in a single business segment, namely Pharmaceutical Business. Its Pharmaceutical business focuses on Bone and Pain, Transplantation Immunology, and Neurosciences.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 208.21 | |||||
Equity-to-Asset | 0.84 | |||||
Debt-to-EBITDA | 0.02 | |||||
Interest Coverage | 81.85 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 14.75 | |||||
Beneish M-Score | -2.33 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.4 | |||||
3-Year EBITDA Growth Rate | 2.6 | |||||
3-Year EPS without NRI Growth Rate | -5.1 | |||||
3-Year FCF Growth Rate | 1.4 | |||||
3-Year Book Growth Rate | 1.8 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.29 | |||||
9-Day RSI | 40.16 | |||||
14-Day RSI | 43.12 | |||||
3-1 Month Momentum % | 20.66 | |||||
6-1 Month Momentum % | 144.14 | |||||
12-1 Month Momentum % | 144.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.3 | |||||
Quick Ratio | 4.93 | |||||
Cash Ratio | 4.61 | |||||
Days Inventory | 82.02 | |||||
Days Sales Outstanding | 41.34 | |||||
Days Payable | 87.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Dividend Growth Rate | 35.7 | |||||
Shareholder Yield % | 1.81 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 44.07 | |||||
Operating Margin % | 26.95 | |||||
Net Margin % | 26.38 | |||||
EBITDA Margin % | 37.42 | |||||
FCF Margin % | 12.52 | |||||
OCF Margin % | 12.61 | |||||
ROE % | 12.34 | |||||
ROA % | 10.26 | |||||
ROIC % | 27.13 | |||||
3-Year ROIIC % | -4.2 | |||||
ROC (Joel Greenblatt) % | 2392.13 | |||||
ROCE % | 16.87 | |||||
Years of Profitability over Past 10-Year | 9 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 37.65 | |||||
PE Ratio without NRI | 37.67 | |||||
Shiller PE Ratio | 49.01 | |||||
Price-to-Owner-Earnings | 43.47 | |||||
PEG Ratio | 0.96 | |||||
PS Ratio | 9.93 | |||||
PB Ratio | 4.5 | |||||
Price-to-Tangible-Book | 4.5 | |||||
Price-to-Free-Cash-Flow | 79.36 | |||||
Price-to-Operating-Cash-Flow | 78.77 | |||||
EV-to-EBIT | 22.2 | |||||
EV-to-EBITDA | 21.91 | |||||
EV-to-Revenue | 8.2 | |||||
EV-to-FCF | 61.42 | |||||
Price-to-GF-Value | 1.43 | |||||
Price-to-Projected-FCF | 3.53 | |||||
Price-to-Median-PS-Value | 2.42 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.51 | |||||
Price-to-Graham-Number | 2.81 | |||||
| Price-to-Net-Current-Asset-Value | 6.06 | |||||
| Price-to-Net-Cash | 7.25 | |||||
Earnings Yield (Greenblatt) % | 4.5 | |||||
FCF Yield % | 1.25 | |||||
Forward Rate of Return (Yacktman) % | 21.17 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Novartis India Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 3,705.9 | ||
| EPS (TTM) (₹) | 39.61 | ||
| Beta | 0.3621 | ||
| 3-Year Sharpe Ratio | 0.59 | ||
| 3-Year Sortino Ratio | 3.77 | ||
| Volatility % | 71.33 | ||
| 14-Day RSI | 43.12 | ||
| 14-Day ATR (₹) | 76.752132 | ||
| 20-Day SMA (₹) | 1567.545 | ||
| 12-1 Month Momentum % | 144.14 | ||
| 52-Week Range (₹) | 672.25 - 1780 | ||
| Shares Outstanding (Mil) | 24.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Novartis India Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Novartis India Ltd Stock Events
| Event | Date | Price (₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Novartis India Ltd Frequently Asked Questions
What is Novartis India Ltd(NSE:NOVARTIND)'s stock price today?
The current price of NSE:NOVARTIND is ₹1486.30. The 52 week high of NSE:NOVARTIND is ₹1780.00 and 52 week low is ₹672.25.
When is next earnings date of Novartis India Ltd(NSE:NOVARTIND)?
The next earnings date of Novartis India Ltd(NSE:NOVARTIND) is .
Does Novartis India Ltd(NSE:NOVARTIND) pay dividends? If so, how much?
Novartis India Ltd(NSE:NOVARTIND) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Novartis India Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers